Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia

publication date: Jun 17, 2019

Jiangsu Hengrui Medicine in-licensed greater China rights to a treatment for chronic yeast infections from Mycovia Pharma of Durham, North Carolina. Mycovia is currently conducting a Phase III trial of VT-1161 (otesaconazole) in women with recurrent vulvovaginal candidiasis (RVVC) in the US, the EU and Japan. A novel oral therapy, VT-1161 is designed to have greater selectivity, fewer side effects and improved potency than current treatments. Mycovia believes it may also be effective for other systemic fungal infections. More details....

Stock Symbol: (SHA: 600276)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here